

1. Molina, P. E. et al. Modulation of Gut-Specific Mechanisms by Chronic Delta-Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis. *AIDS Res Hum Retroviruses* (2014).
2. Avraham, H. K. et al. Impaired Neurogenesis by HIV-1-Gp120 is Rescued by genetic deletion of Fatty Acid Amide Hydrolase Enzyme. *Br J Pharmacol* (2014).
3. Hazekamp, A. & Heerdink, E. R. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. *Eur J Clin Pharmacol* (2013).
4. Lutge, E. E., Gray, A. & Siegfried, N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database Syst Rev* **4**, CD005175 (2013).
5. Masciotra, S. et al. TEMPORARY REMOVAL: Performance of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. *J Clin Virol* (2013).
6. Stekler, J. D. et al. Relative accuracy of serum, whole blood, and oral fluid HIV tests among Seattle men who have sex with men. *J Clin Virol* **58 Suppl 1**, e119-e122 (2013).
7. Hecht, M. et al. Cytotoxic effect of Efavirenz is selective against cancer cells and associated with the cannabinoid system. *AIDS* (2013).
8. Lapovok, I. et al. Analysis of HIV-1 primary drug resistance in Kazakhstan. *J Int AIDS Soc* **15**, 18209 (2012).
9. Winsauer, P. J. et al. Tolerance to chronic delta-9-tetrahydrocannabinol (Delta(9)-THC) in rhesus macaques infected with simian immunodeficiency virus. *Exp Clin Psychopharmacol* **19**, 154-172 (2011).
10. Hu, S., Sheng, W. S. & Rock, R. B. Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis. *J Neuroimmune Pharmacol* **6**, 528-539 (2011).
11. Costs of compassion club marijuana to be covered. *HIV AIDS Policy Law Rev* **15**, 48 (2011).
12. Molina, P. E. et al. Cannabinoid Neuroimmune Modulation of SIV Disease. *J Neuroimmune Pharmacol* (2011).
13. Molina, P. E. et al. Cannabinoid administration attenuates the progression of simian immunodeficiency virus. *AIDS Res Hum Retroviruses* **27**, 585-592 (2011).
14. Kim, H. J., Shin, A. H. & Thayer, S. A. Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. *Mol Pharmacol* **80**, 357-366 (2011).
15. Wang, X. & Ho, W. Z. Drugs of abuse and HIV infection/replication: Implications for mother-fetus transmission. *Life Sci* (2010).
16. Molina, P. E. et al. Cannabinoid Administration Attenuates the Progression of Simian Immunodeficiency Virus. *AIDS Res Hum Retroviruses* (2010).
17. Lu, T. S. et al. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. *J Immunol* **181**, 6406-6416 (2008).
18. Beaulieu, P. & Ware, M. Reassessment of the role of cannabinoids in the management of pain. *Curr Opin Anaesthesiol* **20**, 473-477 (2007).

19. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. *AIDS Care S* **19**, 295-301 (2007).
20. Ugen, K. E. & Nyland, S. B. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy. *Springer Semin Immunopathol* **28**, 281-287 (2006).
21. Ware, M. A., Ducruet, T. & Robinson, A. R. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. *Harm Reduct J* **3**, 32 (2006).
22. Cabral, G. A. Drugs of abuse, immune modulation, and AIDS. *J Neuroimmune Pharmacol* **1**, 280-295 (2006).
23. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. *J Immunol* **175**, 3990-3999 (2005).
24. Prentiss, D., Power, R., Balmas, G., Tzuang, G. & Israelski, D. M. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. *J Acquir Immune Defic Syndr* **35**, 38-45 (2004).
25. Kosel, B. W. et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. *AIDS* **16**, 543-550 (2002).
26. Researchers seek solutions to diarrhea, wasting. Research takes several different twists and turns. *AIDS Alert* **16(3)**, 38-39 (2001).
27. listed, N. Nausea and vomiting associated with HIV therapy are reduced with Marinol. *AIDS Read* **10**, 701-702 (2000).
28. James, J. S. Marijuana safety study completed: weight gain, no safety problems. *AIDS Treat News* 3-4 (2000).
29. Wallace, J. M. et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. *Chest* **114**, 131-137 (1998).
30. Timour, K. Recreational drugs, methadone and protease inhibitors. *Body Posit* **11(4-5)**, 34 (1998).
31. Stefano, G. B., Salzet, M. & Bilfinger, T. V. Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. *J Cardiovasc Pharmacol* **31**, 862-868 (1998).
32. Gurwitz, D. & Kloog, Y. Do endogenous cannabinoids contribute to HIV-mediated immune failure? *Mol Med Today* **4**, 196-200 (1998).
33. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. *Immunopharmacology* **40**, 179-185 (1998).
34. Gorter, R. Cannabis and cannabidiol: interview with Robert Gorter, M.D. Interview by Fred Gardner. *AIDS Treat News* **No 305**, 4-6 concl (1998).
35. Corcoran, C. Approaches to the AIDS Wasting Syndrome. *Posit Dir News* **10(2)**, 24-27 (1998).
36. Calhoun, S. R., Galloway, G. P. & Smith, D. E. Abuse potential of dronabinol (Marinol). *J Psychoactive Drugs* **30**, 187-196 (1998).
37. Timpone, J. G. et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. *AIDS Res Hum Retroviruses* **13**, 305-315 (1997).

38. Whitfield, R. M., Bechtel, L. M. & Starich, G. H. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy. *Alcohol Clin Exp Res* **21**, 122-127 (1997).
39. Tashkin, D. P., Roth, M. D. & Dubinett, S. M. Medicinal marijuana? *N Engl J Med* **336(16)**, 1186; author reply 1186-1186; author reply 1187 (1997).
40. Medical marijuana. *AIDS Policy Law* **12(20)**, 16 (1997).
41. How should employer respond to pilot's HIV medicine? *AIDS Policy Law* **12(20)**, 6-7 (1997).
42. Patrick, D. M. et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. *Int J STD AIDS* **8**, 437-445 (1997).
43. Reiter, G. S. The HIV wasting syndrome. *AIDS Clin Care* **8(11)**, 89-91, 93, 96 (1996).
44. Beal, J. & Flynn, N. AIDS-associated anorexia. *J Physicians Assoc AIDS Care* **2**, 19-22 (1995).
45. Struwe, M. et al. Effect of dronabinol on nutritional status in HIV infection. *Ann Pharmacother* **27**, 827-831 (1993).
46. Gorter, R., Seefried, M. & Volberding, P. Dronabinol effects on weight in patients with HIV infection. *AIDS* **6(1)**, 127 (1992).
47. Gorter, R. Management of anorexia-cachexia associated with cancer and HIV infection. *Oncology (Huntingt)* **5**, 13-17 (1991).